Prelude Therapeutics Incorporated

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate its KAT6A selective degrader PRT13722 in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo) in HR+/HER2- breast cancer. The FDA recently cleared the Phase 1 IND for PRT13722, with monotherapy dose escalation beginning in Q4 2026 followed by combination cohorts. Preclinical data presented at AACR 2026 showed monotherapy efficacy and synergy with CDK4/6 inhibitors and endocrine therapies. Prelude retains full global development and commercial rights to the wholly owned program.

•19d ago

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

The FDA cleared Prelude Therapeutics' Investigational New Drug application for PRT13722, a first-in-class oral KAT6A selective degrader for HR+/HER2- breast cancer, with patient enrollment in the Phase 1 study expected to begin in the fourth quarter of 2026. The Phase 1 is a first-in-human, open-label, multicenter study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer. Prelude's differentiation argument is that selectively degrading KAT6A while sparing KAT6B may maximize the therapeutic window, avoiding the overlapping toxicities that dual KAT6A/B inhibitors have shown with current backbone therapies in earlier lines of treatment.

•1mo ago

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics reported Q2 2026 financial results, highlighted by a cash runway extension into the second quarter of 2028 supported by $155.2 million in liquidity. The company posted revenue of $5.7 million and a net loss of $0.14 per share, significantly narrowing the loss compared to the prior year due to reduced operating expenses and workforce reductions. Operationally, Prelude remains on track to initiate the Phase 1 trial of PRT13722 in Q4 2026, while enrollment continues for the PRT12396 study in myeloproliferative neoplasms.

•2mo ago